María Carmen González-Vela

María Carmen González-Vela

Auto-generated profile, based on publicly available information

María Carmen González-Vela

Pathology Department, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
NGNuria García-Díaz
Nuria García-Díaz
BERTA CASARBERTA CASAR
BERTA CASAR
RARuth Alonso-Alonso
Ruth Alonso-Alonso
LQLaura Quevedo
Laura Quevedo
SRSocorro María Rodríguez-Pinilla
Socorro María Rodríguez-Pinilla
JVJosé Pedro Vaqué
José Pedro Vaqué
Developing mechanistic rationales can improve the clinical management of cutaneous T-cell lymphomas. There is considerable genetic and biological evidence of a malignant network of signaling mechanisms, highly influenced by deregulated TCR/PLCγ1 activity, controlling the biology of these lesions. In addition, activated signal transducer and activator of transcription 3 is associated with clinical progression, although the alterations responsible for this have not been fully elucidated. Here, we studied PLCγ1-dependent mechanisms that can mediate STAT3 activation and control tumor growth and progression. Downstream of PLCγ1, the pharmacological inhibition and genetic knockdown of protein kinase C theta (PKCθ) inhibited signal transducer and activator of transcription 3 activation, impaired proliferation, and promoted apoptosis in cutaneous T-cell lymphoma cells. A PKCθ-dependent transcriptome in mycosis fungoides/Sézary syndrome cells revealed potential effector genes controlling cytokine signaling, TP53, and actin cytoskeleton dynamics. Consistently, an in vivo chicken embryo model xenografted with mycosis fungoides cells showed that PKCθ blockage abrogates tumor growth and spread to distant organs. Finally, the expression of a number of PKCθ target genes found in mycosis fungoides cells significantly correlated with that of PRKCQ (PKCθ) in 81 human mycosis fungoides samples. In summary, PKCθ can play a central role in the activation of malignant cutaneous T-cell lymphoma mechanisms via multiple routes, including, but not restricted to, STAT3. These mechanisms may, in turn, serve as targets for specific therapies.

2 March 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SDSeyram A. Doe-Tetteh
Seyram A. Doe-Tetteh
SCSabrina Y. Camp
Sabrina Y. Camp
DRDalicia Reales
Dalicia Reales
JCJett Crowdis
Jett Crowdis
ANAnne Marie Noronha
Anne Marie Noronha
DSDavid B. Solit
David B. Solit
Purpose: To overcome barriers to genomic testing for patients with rare cancers, we initiated a program to offer free clinical tumor genomic testing worldwide to patients with select rare cancer subtypes. Experimental Design: Patients were recruited through social media outreach and engagement with disease-specific advocacy groups, with a focus on patients with histiocytosis, germ cell tumors (GCT), and pediatric cancers. Tumors were analyzed using the MSK-IMPACT next-generation sequencing assay with the return of results to patients and their local physicians. Whole-exome recapture was performed for female patients with GCTs to define the genomic landscape of this rare cancer subtype. Results: A total of 333 patients were enrolled, and tumor tissue was received for 288 (86.4%), with 250 (86.8%) having tumor DNA of sufficient quality for MSK-IMPACT testing. Eighteen patients with histiocytosis have received genomically guided therapy to date, of whom 17 (94%) have had clinical benefit with a mean treatment duration of 21.7 months (range, 6–40+). Whole-exome sequencing of ovarian GCTs identified a subset with haploid genotypes, a phenotype rarely observed in other cancer types. Actionable genomic alterations were rare in ovarian GCT (28%); however, 2 patients with ovarian GCTs with squamous transformation had high tumor mutational burden, one of whom had a complete response to pembrolizumab. Conclusions: Direct-to-patient outreach can facilitate the assembly of cohorts of rare cancers of sufficient size to define their genomic landscape. By profiling tumors in a clinical laboratory, results could be reported to patients and their local physicians to guide treatment. See related commentary by Desai and Subbiah, p. 2339

25 November 2025
Verified
Other
Open access
SDSeyram A. Doe-Tetteh
Seyram A. Doe-Tetteh
SCSabrina Y. Camp
Sabrina Y. Camp
DRDalicia Reales
Dalicia Reales
JCJett Crowdis
Jett Crowdis
ANAnne Marie Noronha
Anne Marie Noronha
DSDavid B. Solit
David B. Solit
Patient demographic data for the female patients in the Extragonadal GCT cohort (both Make-an-IMPACT and internal MSK patients, n=16)

1 April 2023
Verified
Other
Open access
SDSeyram A. Doe-Tetteh
Seyram A. Doe-Tetteh
SCSabrina Y. Camp
Sabrina Y. Camp
DRDalicia Reales
Dalicia Reales
JCJett Crowdis
Jett Crowdis
ANAnne Marie Noronha
Anne Marie Noronha
DSDavid B. Solit
David B. Solit
Clonality assessment of known oncogenic mutations in the female GCT cohort.

1 April 2023
Verified
Other
Open access
SDSeyram A. Doe-Tetteh
Seyram A. Doe-Tetteh
SCSabrina Y. Camp
Sabrina Y. Camp
DRDalicia Reales
Dalicia Reales
JCJett Crowdis
Jett Crowdis
ANAnne Marie Noronha
Anne Marie Noronha
DSDavid B. Solit
David B. Solit
Clonality assessment of known oncogenic mutations in the female GCT cohort.

5 July 2023
Verified
Other
Open access
PDF file
SDSeyram A. Doe-Tetteh
Seyram A. Doe-Tetteh
SCSabrina Y. Camp
Sabrina Y. Camp
DRDalicia Reales
Dalicia Reales
JCJett Crowdis
Jett Crowdis
ANAnne Marie Noronha
Anne Marie Noronha
DSDavid B. Solit
David B. Solit
Clonality assessment of known oncogenic mutations in the female GCT cohort.